Schwannoma

Jump to navigation Jump to search


For patient information click here

Schwannoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Schwannoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Biopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Schwannoma On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Schwannoma

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Schwannoma

CDC on Schwannoma

Schwannoma in the news

Blogs on Schwannoma

Directions to Hospitals Treating Schwannoma

Risk calculators and risk factors for Schwannoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2]

Synonyms and keywords: Neurilemmoma, Neurinoma, Neurolemmoma, Schwann cell tumor, Schwannomatosis

Overview

Schwannomas are benign tumors of Schwann cell origin and are the most common tumor of peripheral nerves, including cranial nerves.

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Schwannoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

WikiDoc Resources for Schwannoma

Articles

Most recent articles on Schwannoma

Most cited articles on Schwannoma

Review articles on Schwannoma

Articles on Schwannoma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Schwannoma

Images of Schwannoma

Photos of Schwannoma

Podcasts & MP3s on Schwannoma

Videos on Schwannoma

Evidence Based Medicine

Cochrane Collaboration on Schwannoma

Bandolier on Schwannoma

TRIP on Schwannoma

Clinical Trials

Ongoing Trials on Schwannoma at Clinical Trials.gov

Trial results on Schwannoma

Clinical Trials on Schwannoma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Schwannoma

NICE Guidance on Schwannoma

NHS PRODIGY Guidance

FDA on Schwannoma

CDC on Schwannoma

Books

Books on Schwannoma

News

Schwannoma in the news

Be alerted to news on Schwannoma

News trends on Schwannoma

Commentary

Blogs on Schwannoma

Definitions

Definitions of Schwannoma

Patient Resources / Community

Patient resources on Schwannoma

Discussion groups on Schwannoma

Patient Handouts on Schwannoma

Directions to Hospitals Treating Schwannoma

Risk calculators and risk factors for Schwannoma

Healthcare Provider Resources

Symptoms of Schwannoma

Causes & Risk Factors for Schwannoma

Diagnostic studies for Schwannoma

Treatment of Schwannoma

Continuing Medical Education (CME)

CME Programs on Schwannoma

International

Schwannoma en Espanol

Schwannoma en Francais

Business

Schwannoma in the Marketplace

Patents on Schwannoma

Experimental / Informatics

List of terms related to Schwannoma

Epidemiology

Peak presentation is in the 5th-6th decades. When they occur in patients with neurofibromatosis type 2 (NF2), schwannomas usually present by the 3rd decade 4. There is no sex predilection.

Associations

Most schwannomas are solitary (90%) 2 and sporadic, however, there is an association with NF2(abnormality of chromosome 22). Multiple schwannomas are characteristic of NF2. Approximately 18% of solitary schwannomas occur in patients with NF2 4.

There is also schwannomatosis, which consists of multiple schwannomas without the concomitant involvement of cranial nerve VIII.

Clinical presentation

Presentation depends on the location of the tumor (see below) but generally, symptoms are due to local mass effect or dysfunction of the nerve they arise from.

Pathology

Macroscopic appearance

Schwannomas are benign encapsulated neoplasms of Schwann cells (WHO grade I). They arise eccentrically from their parent nerve, with the nerve fibers splayed along their surface (as distinct to neurofibromas which arise within the nerve).

Microscopic appearance

Conventional schwannomas are composed of spindle cells which demonstrate two growth patterns: Antoni type A and Antoni type B 7,8.

Antoni type A pattern: elongated cells are densely packed and arranged in fascicles. Palisades are sometimes seen; when prominent these form Verocay bodies.

Antoni type B pattern cells are less compact and are prone to cystic degeneration.

Variants

Schwannoma variants include 6,8:

  • ancient schwannoma
  • cellular schwannoma
    • predominantly composed of Antoni A tissue
    • no Verocay bodies
    • most commonly found in a paravertebral location, or trigeminal nerves (CN V)
  • melanotic schwannoma: dense melanin pigment
  • plexiform schwannoma
    • usually arise from skin or subcutaneous tissues
    • usually diagnosed at birth or childhood
    • usually sporadic, but rarely associated with NF2
    • should not be confused with plexiform neurofibromas
      • associated with NF1
      • may undergo malignant change
Locations
  • intracranial schwannomas
    • cranial nerves: although almost any cranial nerve may be involved, except olfactory nerves and optic nerves which lack sheaths composed of Schwann cells, by far the most commonly involved nerve is the vestibulocochlear nerve (CN VIII)
    • non-cranial nerve or intracerebral (very rare)
  • spinal schwannoma
    • arising from spinal nerve roots  
  • trunk
    • intercostal nerves – see intercostal nerve schwannoma
    • posterior mediastinum
    • retroperitoneum
    • gastrointestinal schwannoma
  • limbs
    • especially flexor surfaces (specifically ulnar and peroneal nerves)

Radiographic features

General imaging features of schwannomas include:

  • well circumscribed masses which displace adjacent structures without direct invasion
  • cystic and fatty degeneration are common 4
  • the larger a schwannoma, the more likely it is to show heterogeneity because of cystic degeneration or hemorrhage 3
  • hemorrhage occurs in 5% of cases 3
  • calcification is rare
CT

CT is not as sensitive or specific for the diagnosis of schwannoma as MRI but is often the first investigation obtained. It is particularly useful in assessing bony changes adjacent to the tumor.

Imaging features include:

  • low to intermediate attenuation
  • intense contrast enhancement
    • small tumors typically demonstrate homogeneous enhancement
    • larger tumors may show heterogeneous enhancement
  • adjacent bone remodelling with smooth corticated edges
MRI

Schwannomas have fairly predictable signal characteristics 7:

  • T1: isointense or hypointense
  • T1 C+ (Gd): intense enhancement
  • T2: heterogeneously hyperintense (Antoni A: relatively low, Antoni B: high)
    • cystic degenerative areas may be present, especially in larger tumors
  • T2*: larger tumors often have areas of hemosiderin

A number of signs can also be useful:

  • split-fat sign: thin peripheral rim of fat best seen on planes along long axis of the lesion in non-fat-suppressed sequences
  • target sign
    • peripheral high T2 signal
    • central low signal
    • rarely seen intracranially 7
  • fascicular sign: multiple small ring-like structures

Treatment and prognosis

Schwannomas are slow-growing lesions. Surgery is the treatment of choice. As schwannomas do not infiltrate the parent nerve, they can usually be separated from it. Recurrence is unusual, even after complete resection. They almost never undergo malignant change.

Overview

Schwannomatosis is one form of a genetic disorder called Neurofibromatosis (NF) that has only recently been recognized. It is a rare disorder, affecting only around 1:40,000 individuals.

Symptoms

  • Schwannomas occur instead of Neurofibromas.
  • Multiple Schwannomas occur.
  • The Schwannomas develop on cranial, spinal and peripheral nerves.
  • Chronic pain, and sometimes numbness, tingling and weakness.
  • About 1/3 of patients have segmental Schwannomatosis, which means that the Schwannomas are limited to a single part of the body, such as an arm, a leg or the spine.
  • There are several cases where people with Schwannomatosis have developed a vestibular Schwannoma (acoustic neuroma).
  • Patients with Schwannomatosis do not have learning disabilities related to the disease.
  • Symptoms are generally brought on by hormonal changes such as puberty and pregnancy.

Cause

  • Like the NF1 and NF2 genes, the candidate Schwannomatosis gene, named INI1, is a tumor suppressor that regulates cell cycle, growth and differentiation. INI1 is also known as SMARCB1, hSNF5, or BAF47, and lies on human Chromosome 22. INI1 is also mutated in other tumors including malignant brain & kidney tumors in infants.
  • Schwannomatosis is known to be a genetic disorder, however it can skip generations.

Treatment

  • If feasible, the Schwannomas can be surgically removed. Any tumor-associated pain usually subsides after tumor removal. Damaged nerves and scar tissue can be a result of surgery and pain can be an ongoing problem.
  • Sometimes, a tumor will reappear at the same site after surgery.
  • If surgery is unfeasible, then pain management will have to be used. Schwannomatosis can sometimes cause severe, untreatable pain over time.
  • Other than surgery and/or pain management, there are no other medical treatments available. There are no drugs available to treat Schwannomatosis.
  • Gamma knife surgery can be performed on head tumors to help slow growth of a tumor, although there is no guarantee that it will work.
  • Recently, many advances are being made in the treatment of schwannomas. Of interest is CyberKnife, manufactured by Accuray. Success rates, although limited in data, appear to be in the low to mid ninety percent range.

Template:WikiDoc Sources

Diagnosis

Staging | History and Symptoms | Physical Examination | Laboratory Findings | X Ray | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies | Biopsy

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Related Chapters

Template:Nervous tissue tumors


Template:WikiDoc Sources